Meeting Banner
Abstract #1117

MRI at 7 T Correlates Therapy-Induced Alterations in T2 heterogeneity, ADC and Tumor Volume in Ewings Sarcoma Xenografts

Parastou Foroutan 1 , Christopher L Cubitt 2 , Jillaina L Menth 3 , Damon Reed 4 , Olya Grove 1 , David L Morse 1 , Daniel Sullivan 5 , Robert J Gillies 1 , and Gary V Martinez 1

1 Cancer Imaging & Metabolism, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States, 2 Experimental Therapeutics Program / Translational Research Lab, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States, 3 Translational Research Lab, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States, 4 Experimental Therapeutics Program / Sarcoma Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States, 5 Experimental Therapeutics Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

In spite of the progress with targeted therapies, response rates for Ewings sarcoma (ES), one of the most aggressive human malignancies, still remains poor. In addition, imaging approaches assessing therapeutic response is lacking, as current indices (volume/diameter) do not accurately correlate with changes in tumor biology. Herein, profound MRI analyses were developed to evaluate imaging biomarkers for Dasatinib and Triciribine treated ES xenografts. Notably, we showed that inhibited tumor growth was presaged by elevations in ADC, ADC distribution and T2 heterogeneity. This approach accentuates the role of ADC as a quantitative imaging biomarker for response and shows promising clinical relevance in the sarcoma patient population.

This abstract and the presentation materials are available to members only; a login is required.

Join Here